Lucid Diagnostics Inc. (LUCD)

$0.7508

-0.05

(-5.74%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Lucid Diagnostics Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 159.0K → 1.04M (in $), with an average increase of 52.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -14.20M → -10.83M (in $), with an average increase of 31.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 79.6%

Performance

  • $0.74
    $0.82
    $0.75
    downward going graph

    1.33%

    Downside

    Day's Volatility :9.2%

    Upside

    7.98%

    downward going graph
  • $0.74
    $1.85
    $0.75
    downward going graph

    1.37%

    Downside

    52 Weeks Volatility :60.02%

    Upside

    59.46%

    downward going graph

Returns

PeriodLucid Diagnostics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-44.3%
-0.7%
0.0%
6 Months
-38.73%
9.2%
0.0%
1 Year
-47.94%
3.5%
-1.3%
3 Years
-93.23%
12.3%
-22.1%

Highlights

Market Capitalization
38.4M
Book Value
- $0.49
Earnings Per Share (EPS)
-1.26
Wall Street Target Price
3.83
Profit Margin
0.0%
Operating Margin TTM
-1101.25%
Return On Assets TTM
-101.38%
Return On Equity TTM
-507.97%
Revenue TTM
2.4M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
828.5999999999999%
Gross Profit TTM
-3.2M
EBITDA
-46.0M
Diluted Eps TTM
-1.26
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.0
EPS Estimate Next Year
-0.83
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Lucid Diagnostics Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 410.12%

Current $0.75
Target $3.83

Technicals Summary

Sell

Neutral

Buy

Lucid Diagnostics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lucid Diagnostics Inc.
Lucid Diagnostics Inc.
-26.93%
-38.73%
-47.94%
-93.23%
-93.23%
Stryker Corporation
Stryker Corporation
-7.29%
23.47%
7.74%
21.88%
74.06%
Boston Scientific Corp.
Boston Scientific Corp.
0.06%
34.31%
31.15%
57.57%
87.6%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.75%
24.46%
-3.21%
-10.62%
42.46%
Abbott Laboratories
Abbott Laboratories
-2.98%
12.01%
-2.83%
-13.13%
43.98%
Medtronic Plc
Medtronic Plc
-3.21%
9.79%
-10.17%
-39.42%
-5.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lucid Diagnostics Inc.
Lucid Diagnostics Inc.
NA
NA
NA
-1.0
-5.08
-1.01
NA
-0.49
Stryker Corporation
Stryker Corporation
39.69
39.69
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.01
63.01
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.37
37.37
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
32.79
32.79
5.99
4.33
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.14
25.14
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lucid Diagnostics Inc.
Lucid Diagnostics Inc.
Buy
$38.4M
-93.23%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$124.6B
74.06%
39.69
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$99.1B
87.6%
63.01
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.7B
42.46%
37.37
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$182.7B
43.98%
32.79
13.96%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-5.32%
25.14
13.0%

Institutional Holdings

  • Luminus Management, LLC

    1.61%
  • Vanguard Group Inc

    0.69%
  • Nantahala Capital Management, LLC

    0.62%
  • Bridgeway Capital Management, LLC

    0.28%
  • Geode Capital Management, LLC

    0.27%
  • Ayrton Capital LLC

    0.15%

Corporate Announcements

  • Lucid Diagnostics Inc. Earnings

    Lucid Diagnostics Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Lucid Diagnostics Inc.
Employees
70
CEO
Dr. Lishan Aklog M.D.
Industry
Healthcare

FAQs